AU2020353676B2 - Methods for treating hyperphenylalaninemia - Google Patents

Methods for treating hyperphenylalaninemia

Info

Publication number
AU2020353676B2
AU2020353676B2 AU2020353676A AU2020353676A AU2020353676B2 AU 2020353676 B2 AU2020353676 B2 AU 2020353676B2 AU 2020353676 A AU2020353676 A AU 2020353676A AU 2020353676 A AU2020353676 A AU 2020353676A AU 2020353676 B2 AU2020353676 B2 AU 2020353676B2
Authority
AU
Australia
Prior art keywords
day
sepiapterin
subject
per liter
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020353676A
Other languages
English (en)
Other versions
AU2020353676A1 (en
Inventor
Niel SMITH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PTC Therapeutics MP Inc
Original Assignee
PTC Therapeutics MP Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72827023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2020353676(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by PTC Therapeutics MP Inc filed Critical PTC Therapeutics MP Inc
Publication of AU2020353676A1 publication Critical patent/AU2020353676A1/en
Application granted granted Critical
Publication of AU2020353676B2 publication Critical patent/AU2020353676B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2020353676A 2019-09-25 2020-09-25 Methods for treating hyperphenylalaninemia Active AU2020353676B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962905720P 2019-09-25 2019-09-25
US62/905,720 2019-09-25
PCT/US2020/052871 WO2021062264A1 (en) 2019-09-25 2020-09-25 Methods for treating hyperphenylalaninemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2026210746A Division AU2026210746A1 (en) 2019-09-25 2026-07-29 Methods for treating hyperphenylalaninemia

Publications (2)

Publication Number Publication Date
AU2020353676A1 AU2020353676A1 (en) 2022-04-14
AU2020353676B2 true AU2020353676B2 (en) 2026-04-30

Family

ID=72827023

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020353676A Active AU2020353676B2 (en) 2019-09-25 2020-09-25 Methods for treating hyperphenylalaninemia

Country Status (23)

Country Link
US (1) US20220362249A1 (cg-RX-API-DMAC7.html)
EP (1) EP4034122B1 (cg-RX-API-DMAC7.html)
JP (2) JP7661315B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220070477A (cg-RX-API-DMAC7.html)
CN (1) CN114650825A (cg-RX-API-DMAC7.html)
AU (1) AU2020353676B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022003719A2 (cg-RX-API-DMAC7.html)
CA (1) CA3150003A1 (cg-RX-API-DMAC7.html)
DK (1) DK4034122T3 (cg-RX-API-DMAC7.html)
ES (1) ES3041002T3 (cg-RX-API-DMAC7.html)
FI (1) FI4034122T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251268T1 (cg-RX-API-DMAC7.html)
HU (1) HUE073483T2 (cg-RX-API-DMAC7.html)
IL (1) IL291565B1 (cg-RX-API-DMAC7.html)
JO (1) JOP20220042A1 (cg-RX-API-DMAC7.html)
LT (1) LT4034122T (cg-RX-API-DMAC7.html)
MX (1) MX2022003585A (cg-RX-API-DMAC7.html)
PL (1) PL4034122T3 (cg-RX-API-DMAC7.html)
PT (1) PT4034122T (cg-RX-API-DMAC7.html)
RS (1) RS67295B1 (cg-RX-API-DMAC7.html)
SI (1) SI4034122T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500493T1 (cg-RX-API-DMAC7.html)
WO (1) WO2021062264A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
WO2018102315A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymoprhs of sepiapterin and salts thereof
MX2020002271A (es) 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
CA3102105A1 (en) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
JP7778477B2 (ja) 2018-05-30 2025-12-02 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンの薬学的に許容される塩
JP7502197B2 (ja) 2018-05-30 2024-06-18 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリン血漿曝露を増加させるための方法
LT4009978T (lt) 2019-08-05 2024-11-25 Ptc Therapeutics Mp, Inc. Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui
US12691119B2 (en) 2021-02-09 2026-07-28 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019046849A1 (en) * 2017-09-01 2019-03-07 Censa Pharmaceuticals Inc. PHARMACEUTICAL COMPOSITION COMPRISING SEPAPTERINE AND USES THEREOF

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
ES2586945T3 (es) * 2014-03-31 2016-10-19 Vasopharm Gmbh Composiciones farmacéuticas sólidas que comprenden derivados de biopterina y usos de dichas composiciones
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
WO2018102315A1 (en) * 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymoprhs of sepiapterin and salts thereof
JP7778477B2 (ja) 2018-05-30 2025-12-02 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンの薬学的に許容される塩

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019046849A1 (en) * 2017-09-01 2019-03-07 Censa Pharmaceuticals Inc. PHARMACEUTICAL COMPOSITION COMPRISING SEPAPTERINE AND USES THEREOF

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CURTIUS H CH ET AL: "Atypical phenylketonuria due to tetrahydrobiopterin deficiency. Diagnosis and treatment with tetrahydrobiopterin, dihydrobiopterin and sepiapterin", Clin chim acta, vol. 93, no. 2. DOI: 10.1016/0009-8981(79)90097-4 *
NEIL, S ET AL: "Phase I clinical evaluation of CNSA-001 (sepiapterin), a novel pharmacological treatment for phenylketonuria and tetrahydrobiopterin deficiencies, in healthy volunteers", Mol genet metab, DOI: 10.1016/J.YMGME.2019.02.001 *

Also Published As

Publication number Publication date
MX2022003585A (es) 2022-04-19
ES3041002T3 (en) 2025-11-06
JP2022549834A (ja) 2022-11-29
JOP20220042A1 (ar) 2023-01-30
BR112022003719A2 (pt) 2022-05-31
DK4034122T3 (da) 2025-09-15
EP4034122A1 (en) 2022-08-03
FI4034122T3 (fi) 2025-10-08
RS67295B1 (sr) 2025-11-28
HRP20251268T1 (hr) 2025-12-05
PT4034122T (pt) 2025-09-18
WO2021062264A1 (en) 2021-04-01
SMT202500493T1 (it) 2026-01-12
HUE073483T2 (hu) 2026-01-28
JP2025111476A (ja) 2025-07-30
IL291565B1 (en) 2026-04-01
SI4034122T1 (sl) 2025-12-31
KR20220070477A (ko) 2022-05-31
US20220362249A1 (en) 2022-11-17
CN114650825A (zh) 2022-06-21
EP4034122B1 (en) 2025-08-13
CA3150003A1 (en) 2021-04-01
PL4034122T3 (pl) 2026-01-26
IL291565A (en) 2022-05-01
AU2020353676A1 (en) 2022-04-14
LT4034122T (lt) 2025-11-10
JP7661315B2 (ja) 2025-04-14

Similar Documents

Publication Publication Date Title
EP4034122B1 (en) Methods for treating hyperphenylalaninemia
US12213982B2 (en) Pharmaceutical compositions comprising sepiapterin and uses thereof
EP3801534B1 (en) Treatment of phenylketonuria with sepiapterin
US20230321021A1 (en) Methods of normalizing amino acid metabolism
EP3801536B1 (en) Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure
CN111050764A (zh) β-羟基丁酸酯和丁二醇的S对映异构体及其使用方法
JP2015110592A (ja) 皮膚の乾燥予防または改善用経口剤
US20210205334A1 (en) Methods and Composition for Increasing Muscle Protein Synthesis and/or Functional Strength in Mammals
US20240115572A1 (en) Methods for treating glioblastomas with sepiapterin
CA3165636A1 (en) Methods for treating parkinson's disease with sepiapterin
HK40081378A (en) Methods for treating hyperphenylalaninemia
HK40081378B (en) Methods for treating hyperphenylalaninemia
US20240122931A1 (en) Methods for treating covid-19 with sepiapterin
EA047419B1 (ru) Способы лечения гиперфенилаланинемии
EA052959B1 (ru) Способы лечения гиперфенилаланинемии
HK40051961B (en) Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure
HK40051961A (en) Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure